Enveric Biosciences (ENVB)
NASDAQ:ENVB
Top Page
Enveric Biosciences
(NASDAQ:ENVB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-46.24% Downside)
Action:ReiteratedDate:03/28/26
The score is primarily weighed down by weak financial performance (no revenue, recurring losses, and ongoing cash burn) alongside a declining capital base despite low leverage. Technicals also indicate a sustained downtrend with negative momentum, while valuation is hard to support with a negative P/E and no dividend yield.
Positive Factors
Strengthening patent portfolio
A newly issued U.S. patent broadens composition and method protection for novel therapeutic molecules. Durable patent coverage supports exclusivity, licensing and partnership discussions, and creates multi-year protection that underpins long-term commercial and strategic value.
Negative Factors
No revenue and persistent net losses
A multi-year absence of revenue means the business lacks commercial validation and must rely on financing to fund operations. Persistent net losses increase execution risk, lengthen the path to self-sufficiency, and make achievement of sustainable profitability contingent on successful clinical outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthening patent portfolio
A newly issued U.S. patent broadens composition and method protection for novel therapeutic molecules. Durable patent coverage supports exclusivity, licensing and partnership discussions, and creates multi-year protection that underpins long-term commercial and strategic value.
Read all positive factors
Enveric Biosciences (ENVB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.83M
Dividend YieldN/A
Average Volume (3M)781.31K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth79.45%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.85
Shares Outstanding1,887,535
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.37
Enterprise Value/Ebitda0.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Enveric Biosciences Business Overview & Revenue Model
Company Description
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer rel...
How the Company Makes Money
null...
Enveric Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -200.86K | -337.49K | -408.03K | -435.20K | -681.61K |
| EBITDA | -8.57M | -9.23M | -16.85M | -19.52M | -55.74M |
| Net Income | -12.13M | -9.57M | ― | -18.50M | -48.98M |
Balance Sheet | |||||
| Total Assets | 5.10M | 3.08M | 4.30M | 19.55M | 26.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.68M | 2.24M | 2.29M | 17.72M | 17.36M |
| Total Debt | 0.00 | 0.00 | 0.00 | 63.82K | 176.30K |
| Total Liabilities | 918.40K | 1.49M | 2.34M | 4.00M | 4.41M |
| Stockholders Equity | 4.18M | 1.59M | 1.96M | 14.67M | 22.31M |
Cash Flow | |||||
| Free Cash Flow | -8.14M | -7.73M | -14.10M | -17.73M | -12.32M |
| Operating Cash Flow | -8.14M | -7.73M | -14.09M | -17.15M | -11.46M |
| Investing Cash Flow | 0.00 | 0.00 | 11.67K | -584.16K | 2.19M |
| Financing Cash Flow | 10.58M | 7.67M | -1.34M | 18.18M | 24.90M |
Enveric Biosciences Technical Analysis
Positive
3.72
Price Trends
2.37
Negative
3.76
Negative
7.81
Negative
Market Momentum
-0.11
Negative
46.80
Neutral
70.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Positive. The current price of 3.72 is above the 20-day moving average (MA) of 1.96, above the 50-day MA of 2.37, and below the 200-day MA of 7.81, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 46.80 is Neutral, neither overbought nor oversold. The STOCH value of 70.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENVB.
Enveric Biosciences Risk Analysis
Enveric Biosciences disclosed 74 risk factors in its most recent earnings report. Enveric Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enveric Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $4.99M | -0.22 | 1937.42% | ― | ― | -22.52% | |
42 Neutral | $3.83M | -0.10 | -262.78% | ― | ― | 79.45% | |
42 Neutral | $1.97M | -0.37 | -63.03% | ― | -100.00% | 86.75% | |
42 Neutral | $3.59M | -0.13 | -317.98% | ― | ― | 34.57% | |
41 Neutral | $14.18M | -0.15 | -356.99% | ― | ― | 54.62% |
* Healthcare Sector Average
ENVB
Enveric Biosciences
2.03
-11.77
-85.29%
BDRX
Biodexa Pharmaceuticals
0.87
-15.63
-94.71%
INDP
Indaptus Therapeutics
1.60
-11.70
-87.97%
GTBP
GT Biopharma
0.45
-1.81
-80.13%
ARTL
Artelo Biosciences
7.04
-9.16
-56.54%
Enveric Biosciences Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Enveric Biosciences Expands At-The-Market Equity Offering Capacity
Neutral
Feb 6, 2026
On February 6, 2026, Enveric Biosciences, Inc. filed a prospectus supplement to register an additional $1,346,000 of common stock under its existing At The Market Offering Agreement with H.C. Wainwright Co., LLC, expanding its capacity to raise c...
Business Operations and StrategyPrivate Placements and Financing
Enveric Biosciences Raises Capital Through Equity Offering
Neutral
Jan 28, 2026
On January 27, 2026, Enveric Biosciences entered into securities purchase agreements with institutional investors for a $1.5 million capital raise via a registered direct offering of 328,802 common shares at $4.41 per share, which closed on Januar...
Business Operations and StrategyRegulatory Filings and Compliance
Enveric Biosciences Releases Updated Investor Presentation Materials
Neutral
Jan 9, 2026
On or about January 9, 2026, Enveric Biosciences prepared new investor presentation materials that its management planned to post on the company’s website and use on an ongoing basis in meetings with current and prospective investors and oth...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.